High-intensity statin therapy daily dose lowers LDL-C on average by 50% or more Moderate-intensity statin therapy daily dose lowers LDL-C on average by 30–50% Low-intensity statin therapy daily dose lowers LDL–C on average by less than 30% atorvastatin (40†) – 80 mg atorvastatin 10 (20) mg simvastatin 10 mg rosuvastatin 20 (40) mg rosuvastatin (5) 10 mg pravastatin 10 – 20 mg simvastatin 20 – 40 mg‡ lovastatin 20 mg pravastatin 40 (80) mg fluvastatin 20 – 40 mg lovastatin 40 mg pitavastatin 1 mg fluvastatin XL 80 mg fluvastatin 40 mg bid

†Evidence from one randomized controlled trial only: down-titration if unable to tolerate atorvastatin 80 mg in incremental decrease through aggressive lipid-lowering study (IDEAL).

‡Although simvastatin 80 mg was evaluated in randomized controlled trials, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA due to the increased risk of myopathy, including rhabdomyolysis.

Tier 1: lovastatin 10 mg and 20 mg*

Tier 2: lovastatin 40 mg*, pravastatin*, simvastatin*, atorvastatin**

Tier 3: Crestor** Current information is available at Humana.com/druglistsearch

*Moderate-potency statin

**High-potency statin

Tiers 1 through 3 are based on 2017 plan 17216 Walmart Basic PDP.

To view formulary coverage for a specific drug, see Humana's drug lists.

Humana may send faxes or mail letters to healthcare providers concerning treatment of patients with diabetes. These communications may include the names of patients who may benefit from a change in therapy and a list of medication options. Here is a sample fax:

Sample statins use in people with diabetes fax, PDF opens new window

Healthcare providers also may receive information on this topic in their Humana Star Quality Report.